Sept 14 (Reuters) - Oncolytics Biotech Inc ONC.TO :
* Oncolytics Biotech announces first patient treated in muk eleven study
* Oncolytics Biotech - once maximum tolerated dose has been identified with no associated safety issues, 10 additional patients will be enrolled at MTD
* Oncolytics Biotech Inc - preliminary data for Muk Eleven study expected to be available in Q1 2018